ACOR - アコ―ダ・セラピュ―ティクス (Acorda Therapeutics Inc.) アコ―ダ・セラピュ―ティクス

 ACORのチャート


 ACORの企業情報

symbol ACOR
会社名 Acorda Therapeutics Inc (アコ―ダ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アコーダ・セラピューティクス(Acorda Therapeutics Inc.)はバイオ医薬品会社である。同社は神経障害患者を治療する療法の開発に従事する。同社は多発性硬化症(MS)患者の歩行を改善するための10ミリグラム(mg)のAmpyra(dalfampridine)延長放出錠剤を含む3件の米国食品医薬品局(FDA)承認治療薬を販売する。同社はまたZanaflexカプセルとタブレット、痙縮の管理のための短時間作用型の薬であるアメリカ食品医薬品局(FDA)認可薬及び帯状疱疹後神経痛関連の神経障害性疼痛の管理向けのFDA認可皮膚パッチであるQutenzaを販売する。同社はパーキンソン病、偏頭痛、多発性硬化症(MS)等の各種疾患を治療する神経療法のパイプラインを有する。同社の製品候補はレボドパの自己投与吸入用治療製剤であるCVT-301である。   アコ―ダ・セラピュ―ティクスは、米国のバイオ医薬品販売会社。多発性硬化症や脊髄損傷、および神経系の他の疾患の神経機能を改善する新しい治療法の開発および商業化を行う。また、チザニジン塩酸塩を含む「ザナフレックス」錠を販売する。本社は、ニューヨーク州ア―ズリ―。   Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include AMPYRA (dalfampridine), INBRIJA (levodopa inhalation powder), BTT1023 (timolumab), SYN120, rHIgM22, and GGF2 (Cimaglermin alfa). The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.
本社所在地 420 Saw Mill River Road Ardsley NY 10502 USA
代表者氏名 Ron Cohen ロン・コーエン
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 914-347-4300
設立年月日 34759
市場名 NASDAQ National Market System
ipoyear 2006年
従業員数 484人
url www.acorda.com
nasdaq_url https://www.nasdaq.com/symbol/acor
adr_tso
EBITDA EBITDA(百万ドル) 167.04000
終値(lastsale) 17.65
時価総額(marketcap) 838089299.45
時価総額 時価総額(百万ドル) 776.83520
売上高 売上高(百万ドル) 588.93000
企業価値(EV) 企業価値(EV)(百万ドル) 724.12520
当期純利益 当期純利益(百万ドル) -145.06100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Acorda Therapeutics Inc revenues increased less than 1% to $259.5M. Net income totaled $38M vs. loss of $27.1M. Revenues reflect Net product revenues increase of 3% to $253.4M also reflect License revenue decrease from $6.7M to $0K Royalty revenues decrease of 11% to $6.1M. Net income reflects Research and development - decrease of 40% to $54.8M (expense).

 ACORのテクニカル分析


 ACORのニュース

   Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock?  2020/06/09 14:01:00 Zacks Investment Research
Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.
   Acorda (ACOR) Down 11.8% Since Last Earnings Report: Can It Rebound?  2020/06/04 15:31:19 Zacks Investment Research
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y  2020/05/06 17:27:00 Zacks Investment Research
Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-19 pandemic.
   Acorda Therapeutics (ACOR) Reports Q1 Loss, Misses Revenue Estimates  2020/05/05 22:15:14 Zacks Investment Research
Acorda (ACOR) delivered earnings and revenue surprises of -45.71% and -28.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Acorda Reports First Quarter 2020 Financial Results and Provides Business Update  2020/05/05 20:00:00 Business Wire
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2020. “As we continue navigating the unprecedented operating environment created by COVID-19, our entire team remains focused on ensuring that the Parkinson’s disease and multiple sclerosis communities have continued access to Acorda’s critical medications,” said Ron Cohen, M.D., Acorda's President and Chief Executive
   Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock?  2020/06/09 14:01:00 Zacks Investment Research
Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.
   Acorda (ACOR) Down 11.8% Since Last Earnings Report: Can It Rebound?  2020/06/04 15:31:19 Zacks Investment Research
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y  2020/05/06 17:27:00 Zacks Investment Research
Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-19 pandemic.
   Acorda Therapeutics (ACOR) Reports Q1 Loss, Misses Revenue Estimates  2020/05/05 22:15:14 Zacks Investment Research
Acorda (ACOR) delivered earnings and revenue surprises of -45.71% and -28.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Acorda Reports First Quarter 2020 Financial Results and Provides Business Update  2020/05/05 20:00:00 Business Wire
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2020. “As we continue navigating the unprecedented operating environment created by COVID-19, our entire team remains focused on ensuring that the Parkinson’s disease and multiple sclerosis communities have continued access to Acorda’s critical medications,” said Ron Cohen, M.D., Acorda's President and Chief Executive
   Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?  2020/04/24 15:49:00 Zacks Investment Research
During Acorda's (ACOR) upcoming Q1 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug, Inbrija.
   Global Multiple Sclerosis Drugs Market Study, 2020 - Leading Players are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer, Merck & Co, Sanofi, Teva Pharma, GlaxoSmithKline and Acorda Therapeutics - ResearchAndMarkets.com  2020/04/17 15:53:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Multiple Sclerosis Drugs Market Global Report 2020" report has been added to ResearchAndMarkets.com's offering. The global multiple sclerosis drugs market was worth $20.83 billion in 2019. North America is expected to be the largest region in the forecast period. Major players in the market are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer, Merck & Co, Sanofi, Teva Pharmaceutical Industries, GlaxoSmithKline and Acorda Therapeutics. The growth of multiple sc
   Acorda Therapeutics (ACOR) Flat As Market Gains: What You Should Know  2020/04/16 21:45:22 Zacks Investment Research
Acorda Therapeutics (ACOR) closed the most recent trading day at $1.06, making no change from the previous trading session.
   The Inhaler Market in the United States to 2025 - Featuring 3M, Acorda Therapeutics & Adamis Pharmaceuticals Among Others - ResearchAndMarkets.com  2020/04/15 01:18:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "US Inhaler Market 2019-2025" report has been added to ResearchAndMarkets.com's offering. The US inhaler market is anticipated to grow at a substantial rate of 1.3% during the forecast period. The growth of the market of inhaler devices in the US is mainly driven by factors which include the growing prevalence of chronic diseases such as asthma, diabetes, respiratory lung diseases and so on. Asthma is chronic inflammation of the lung airways that causes breathlessne
   Why Is Acorda (ACOR) Down 54.7% Since Last Earnings Report?  2020/03/14 15:30:50 Zacks Investment Research
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アコ―ダ・セラピュ―ティクス ACOR Acorda Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)